Overall, the described involvement of the CCR5 ligands CCL5 and CCL3 in CRC-driven immune escape mechanisms and their tumor-promoting properties seemed to outweigh the capacity of CCL4 to trigger the recruitment of peripheral effector T cells in CRC metastases via CCR5 engagement [57]. The gene discussed is CCL5; the disease is neoplasm.